Liz M. . .A narrative review of the role of transthyretin in health and disease. ” Neurology and Therapy, 9(2020) : 395-402.
Sanguinetti C. .1906 .The journey of human transthyretin: Synthesis, structure stability and catabolism. ”Biomedicines, 10(2022) : .
Corino C. . .Tetrameric transthyretin as a protective factor against Alzheimer's disease. ” Molecular Neurobiology, 62(2025) : 2945-2954.
Ajmal M.R. . .Protein misfolding and aggregation in proteinopathies: Causes, mechanism and cellular response. ” Diseases, 11(2023) : 30.
Almeida Z.L.,R.M.M. Z.L. .2020 .Brito. “Structure and aggregation mechanisms in amyloids. ” Molecules, 25 : 1195.
Plantone D. .2023 .Current evidence supporting the role of immune response in ATTRv amyloidosis. ” Cells, 12(19) : 2383.
Faria T.Q. .2015 .A look into amyloid formation by transthyretin: Aggregation pathway and a novel kinetic model. ” Physical Chemistry Chemical Physics, 17(11) : 7255-7263.
Manso ,Marta .2017 .Senile systemic amyloidosis: An underdiagnosed disease. European Journal of Case Reports in Internal Medicine, 4(9) : 000725.
Manral N.,Reixach N. .2015 .Amyloidogenic and nonamyloidogenic transthyretin variants interact differently with human cardiomyocytes: Insights into early events of nonfibrillar tissue damage. ” Bioscience Reports, 35(6) : .
Guo X. .2020 .Review on the structures and activities of transthyretin amyloidogenesis inhibitors. ” Drug Design, Development and Therapy, 14 : 1057-1081.
Yokoyama T. .2012 .Hydrogen bond network and pH sensitivity in transthyretin: Neutron crystal structure of human transthyretin. ” Journal of Structural Biology, 177 : 283-290.
Zanotti G. .2017 .Structural and dynamics evidence for scaffold asymmetric flexibility of the human transthyretin tetramer. ” PLOS ONE, 0187716(12) : .
Richardson .2005 .Expression of transthyretin in the choroid plexus.” The Blood-Cerebrospinal Fluid Barrier. , : 279-307.
Habib C.,April C. .2022 .Umbilical cord and neonatal transthyretin and their relationship to growth and nutrition in preterm infants. ” Rambam Maimonides Medical Journal, 13(2) : .
Ingenbleek Y.,M. De Visscher Y. .1979 .Hormonal and nutritional status: Critical conditions for endemic goiter epidemiology?” Metabolism. , 28 : 9-19.
Aldred A.R. .1995 .The cerebral expression of plasma protein genes in different species. ” Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 111 : 1-15.
Pfeffer B.A. .2004 .Expression of transthyretin and retinolbinding protein mRNAs and secretion of transthyretin by cultured monkey retinal pigment epithelium. ” Molecular Vision, 10 : 23-30.
Jacobsson B. .1989 .Transthyretin immunoreactivity in human and porcine liver, choroid plexus and pancreatic islets. ” Journal of Histochemistry and Cytochemistry, 37 : 31-37.
Sousa M.M.,Saraiva M.J. .2001 .Internalization of transthyretin: Evidence of a novel yet unidentified receptorassociated protein (RAP)-sensitive receptor. ” Journal of Biological Chemistry, 276 : 14420-14425.
.2010 .Molecular aspects of thyroid hormone actions. ” Endocrine Reviews, 0007 : 139-170.
Palha J.A. .2002 .Thyroid hormone distribution in the mouse brain: The role of transthyretin. ” Neuroscience, 4522(02) : 00163-0.
Patel J. .2011 .Delivery of maternal thyroid hormones to the fetus. ” Trends in Endocrinology and Metabolism, 01 : 164-170.
Gudas L.J. “ .2011 .Emerging roles for retinoids in regeneration and differentiation in normal and disease states. ” Biochimica et Biophysica Acta, 10 : 213-221.
Shearer ,K.D. .2012 .A vitamin for the brain. ” Trends in Neurosciences, 08 : 733-741.
Lerner A.J. .2012 .Retinoids for treatment of Alzheimer's disease. ” Biofactors, 38 : 84-89.
Ono K. .2004 .Vitamin A exhibits potent anti amyloidogenic and fibril destabilizing effects in vitro. ” Experimental Neurology, 05 : 380-392.
Liu H.,MCB H. .2013 .Liver retinol transporter and receptor for serum retinol binding protein (RBP4). ” Molecular and Cellular Biology, 33(11) : 01408-12.
van Bennekum A.M. .2001 .Biochemical basis for depressed serum retinol levels in transthyretin deficient mice. ” Journal of Biological Chemistry, 276 : 1107-1113.
Sousa M.M. .2000 .Transthyretin in high density lipoproteins: Association with apolipoprotein A I.”. Journal of Lipid Research, 41 : 58-65.
Liz M. .2004 .Transthyretin, a new cryptic protease. ” Journal of Biological Chemistry, 279 : 21431-21438.
Liz M. .2007 .ApoA I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. ” Journal of Lipid Research, 48 : JLR200-2395.
Costa R. .2008 .Transthyretin protects against A β peptide toxicity by proteolytic cleavage of the peptide: A mechanism sensitive to the Kunitz protease inhibitor. ” PLOS ONE, 0002899 : .
Fleming C.E. .2007 .Transthyretin enhances nerve regeneration. ” Journal of Neurochemistry, 04864 : 4159-839.
Alshehri B. .2015 .The diversity of mechanisms influenced by transthyretin in neurobiology: Development, disease and endocrine disruption. ” Journal of Neuroendocrinology, 27 : 303-323.
Oliveira S.M. .2011 .Gender dependent transthyretin modulation of brain amyloid β levels: Evidence from a mouse model of Alzheimer's disease. ” Journal of Alzheimer's Disease, 22 : 405-412.
Thomas M.M. .2016 .Multimodality review of amyloid related diseases of the central nervous system. ” Radiographics, 36 : 1147-1163.
Alemi M. . .Transthyretin participates in beta amyloid transport from the brain to the liver-involvement of the low-density lipoprotein receptor related protein 1?” Scientific Reports. , 6(2016) : 20164.
Santos S.D. .2010 .CSF transthyretin neuroprotection in a mouse model of brain ischemia. ” Journal of Neurochemistry, 07080 : 4159-1444.
Gao C. .2011 .Serum prealbumin (transthyretin) predicts good outcomes in young patients with cerebral infarction. ” Clinical and Experimental Medicine, 11 : 49-54.
Vieira M. .1862 .Evidence for synergistic action of transthyretin and IGF-I over the IGF-I receptor. Biochimica et Biophysica Acta - Molecular Cell Research, (2016) : 797-804.
Chiu S.L. . .Insulin receptor signalling regulates synapse number, dendritic plasticity and circuit function in vivo. ” Neuron, 58(2008) : 708-719.
Zawislak A. .2017 .Neuron-derived transthyretin modulates astrocytic glycolysis in hormone-independent manner. ” Oncotarget, 8(63) : 106625-106638.
Laviola L. . .The IGF-I signalling pathway. ” Current Pharmaceutical Design, 13(2007) : 663-669.
Vieira M. . .Transthyretin induces insulin-like growth factor I nuclear translocation regulating its levels in the hippocampus. ” Molecular Neurobiology, 51(2015) : 1468-1479.
Rich L.R. .2019 .The role of brain glycogen in supporting physiological function. , 13 : 1176.
Lee C.C. . .Transthyretin stimulates tumor growth through regulation of tumor, immune and endothelial cells. ” Journal of Immunology, 202(2019) : 991-1002.
Li J. .2025 .Tissue-resident immune cells: From defining characteristics to roles in diseases. ” Signal Transduction and Targeted Therapy, 10 : 12.
Basha S. .2025 .Assessing amyloid fibrils and amorphous aggregates: A review. International Journal of Biological Macromolecules, 143725 : 143725.
Benson M.D. .2018 .Recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. ” Amyloid, 25(2018) : 215-219.
Coelho T. . .THAOS - The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. ” Current Medical Research and Opinion, 29(2013) : 63-76.
Beirão J.M. . .Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: A review of 513 cases. , 22(2015) : 117-122.
Solignac J. .2022 .Kidney involvement in hereditary transthyretin amyloidosis: A cohort study of 103 patients. Clinical Kidney Journal, 15 : 1747-1754.
Carroll A. . .Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. ” Journal of Neurology, Neurosurgery and Psychiatry, 93(2022) : 668-678.
Sekijima Y. . .The biological and chemical basis for tissue-selective amyloid disease. ” Cell, 121(2005) : 73-85.
Koike H. .2016 .Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. ” Neurology, 87(21) : 2220-2229.
Koike H.,Katsuno M. .2021 .The ultrastructure of tissue damage by amyloid fibrils. ” Molecules, 26(15) : 4611.
Rousseau A. .2018 .Angiographic signatures of the predominant form of familial transthyretin amyloidosis (Val30Met mutation). ” American Journal of Ophthalmology, 192 : 169-177.
Rapezzi C. .2009 .Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. ” Circulation, 120(13) : 1203-1212.
Benson M.D.,Kincaid J.C. . .The molecular biology and clinical features of amyloid neuropathy. ” Muscle and Nerve, 36(2007) : 411-423.
Schneider F. . .Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. ” Protein Science, 10(2001) : 1606-1613.
Koike H. .2009 .Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. ” Journal of the Neurological Sciences, 287(2) : 178-184.
Conceição I.,M. De Carvalho I. . .Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late- and early-onset cases in Portugal.” Muscle and Nerve. , 3(2007) : 116-118.
Pinto M.V. . .Neuromuscular amyloidosis: Unmasking the master of disguise. ” Muscle and Nerve, 64(2021) : 23-36.
N.R. .1997 .Intraepidermal nerve fibre density in patients with painful sensory neuropathy. ” Neurology, 48 : 708-711.
Ungerer M.N. . .Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: A 20-year German single-referral centre experience. ” Amyloid, 28(2021) : 91-99.
Duarte A.G. .2019 .Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: A systematic review. ” Clinical Autonomic Research, 29 : 1-9.
Lai ,M.K.L .2020 .A systematic review of developmental lumbar spinal stenosis. ” European Spine Journal, 29 : 2173-2187.
Çakar A. .2020 .Lumbar spinal stenosis: A rare presentation of hereditary transthyretin amyloidosis. NoroPsikiyatri Arsivi, 59 : 77-79.
Wininger A.E. .2021 .Musculoskeletal pathology as an early warning sign of systemic amyloidosis: A systematic review of amyloid deposition and orthopedic surgery. ” BMC Musculoskeletal Disorders, 22 : 51.
Yanagisawa A. .2015 .Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. ” Modern Pathology, 28 : 201-207.
Minnella A.M. . .Ocular involvement in hereditary amyloidosis. ” Genes, 12(2021) : 955.
Lessell S. .1975 .Scalloped pupils in familial amyloidosis. ” New England Journal of Medicine, 293 : 914-915.
Sousa L. .2021 .CNS involvement in hereditary transthyretin amyloidosis. ” Neurology, 97 : 1111-1119.
Brett M. .1999 .Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. ” Brain, 122 : 183-190.
Ellie E. . .Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). ” Neurology, 57(2001) : 135-137.
Jin K. .2004 .Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly representing repeated subarachnoid haemorrhages with superficial siderosis. ” Journal of Neurology, Neurosurgery and Psychiatry, 75 : 1463-1466.
Ruberg F.L. .2019 .Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. ” Journal of the American College of Cardiology, 73(22) : 2872-2891.
Yamamoto T.,Yokochi T. . .Transthyretin cardiac amyloidosis: An update on diagnosis and treatment. ” ESC Heart Failure, 6(2019) : 1128-1139.
Connors L.H. . .Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: A prospective, observational cohort study. ” Circulation, 133(2016) : 282-290.
Fenoglio R. .2022 .Renal involvement in transthyretin amyloidosis: The double presentation of transthyretin amyloidosis deposition disease. ” Nephron, 146 : 481-488.
Bordeneuve pp.V.,G. Said. pp.V. .2011 .Familial amyloid polyneuropathy.” The Lancet Neurology. , 10 : 1086-1097.
Ungericht M. .2023 .Amyloid myopathy: Expanding the clinical spectrum of transthyretin amyloidosis-Case report and literature review. ” Journal of Nuclear Cardiology, 30 : 1420-1426.
Almeida M.R. .2004 .Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 381 : 351-356.
Koike H.,Katsuno M. . .Ultrastructure in transthyretin amyloidosis: From pathophysiology to therapeutic insights. ” Biomedicines, 7(2019) : 11.
Berk J.L. .2013 .Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial. ” JAMA, 310 : 2658-2667.
Maurer M.S. .2018 .Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. ” New England Journal of Medicine, 379(11) : 1007-1016.
Obici L.,Adams D. .2020 .Acquired and inherited amyloidosis: Knowledge driving patients' care. ” Journal of the Peripheral Nervous System, 25 : 85-101.
Aimo A. .2022 .RNA-targeting and gene editing therapies for transthyretin amyloidosis. ” Nature Reviews Cardiology, 19(10) : 655-667.
Solomon S.D. . .Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. ” Circulation, 139(2019) : 431-443.
Vollmar J. .2018 .Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study. Transplant International, 31(11) : 1207-1215.
Sousa M. . .Heart transplantation in cardiac amyloidosis. ” Heart Failure Reviews, 22(2017) : 317-327.